bioMerieux

Near-term caution, conviction unshaken

27/10/26 -"Despite some near-term caution (discussed in the EPS section), we continue to see sizeable upside for bioMerieux, supported by its dominance in multiplex syndromic testing, which is likely to persist ..."

PDF page sample
Pages
66
Language
English
Published on
27/10/26
Download
You may also be interested by these reports :
27/10/26
Despite some near-term caution (discussed in the EPS section), we continue to see sizeable upside for bioMerieux, supported by its dominance in ...
23/10/26
SSB delivered an in-line Q3 26, with revenue and underlying EBITDA in line with consensus. Consumables continued to lead growth, while equipment grew ...
22/10/26
After a failed bid by Thermo Fisher and persistent rumours in recent years, Qiagen shareholders now have a second opportunity. Although shareholder ...
22/10/26
Sartorius reported a strong Q3 26, with revenue (+3.0%) and underlying EBITDA (+4.1%) comfortably ahead of consensus. Operational growth accelerated ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO